COMMUNIQUÉS West-GlobeNewswire

AiBtl BioPharma Inc. Completes $7.6M Land Deal: Exchanging Stock for Real Estate, Demonstrating the Value of ABVC's 23M AiBtl Share Ownership as Hundred Million Dollars
21/03/2024
FREMONT, CA, March 21, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in Oncology/Hematology, [...]
USDA-APHIS Determines that Yield10 Bioscience’s Omega-3 Camelina Varieties May Be Planted and Bred in the United States
21/03/2024
-Yield10 achieves significant milestone enabling ramp-up to commercial scale production of omega-3 fatty acids in Camelina -Omega-3 Camelina potentially represents a novel solution to the market need for omega-3 oils [...]
Landos Biopharma Provides Business Update and Reports Fourth Quarter and Full Year 2023 Results
21/03/2024
Top-line Results from the NEXUS Phase 2 Clinical Trial of NX-13 for Ulcerative Colitis Planned for Q4 2024 Sufficient Cash to Fund Planned Operations into mid-2025 NEW YORK, March 21, 2024 (GLOBE NEWSWIRE) -- Landos [...]
CMR Surgical announces over 20,000 surgical cases completed using Versius
21/03/2024
Over 20,000 surgical cases completed using Versius The versatile surgical robot Versius has now been used to perform over 20,000 surgical cases across seven specialties with data collected in the clinical registry and [...]
Lisata Therapeutics Announces U.S. FDA Rare Pediatric Disease Designation Granted to LSTA1 for the Treatment of Osteosarcoma
21/03/2024
Achieves critical first step toward priority review voucher BASKING RIDGE, N.J., March 21, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical [...]
Daré Bioscience to Host Full Year 2023 Financial Results and Company Update Conference Call and Webcast on March 28, 2024
21/03/2024
SAN DIEGO, March 21, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE ), a leader in women’s health innovation, today announced that it will host a conference call and live webcast at 4:30 p.m. Eastern Time [...]
BioStem Technologies to Report Fourth Quarter 2023 Financial Results on Monday, April 01, 2024
21/03/2024
Conference Call on Monday, April 1st, at 4:30 pm ET POMPANO BEACH, Fla., March 21, 2024 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, [...]
CytomX Therapeutics Appoints Dr. Zhen Su to Board of Directors
21/03/2024
SOUTH SAN FRANCISCO, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced the appointment of Zhen Su [...]
Disc Medicine Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
21/03/2024
Top-line results from AURORA, the placebo-controlled phase 2 study of bitopertin in erythropoietic porphyrias (EPP), expected March / April 2024 On track to deliver multiple read-outs in 2024, including updated results [...]
Acumen Pharmaceuticals to Present Deeper Insights, Including Fluid Biomarker Data for Sabirnetug (ACU193), During Emerging Science Session at the American Academy of Neurology Annual Meeting
21/03/2024
- Company on track to initiate Phase 2 trial evaluating sabirnetug in first half of 2024 CHARLOTTESVILLE, Va., March 21, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage [...]
Tonix Pharmaceuticals Announces Poster Presentation Describing Discovery of Novel Next-Generation Oxytocin Analogues at the American Chemistry Society (ACS) Spring 2024 Meeting
21/03/2024
Four Phase 2 investigator-initiated studies of TNX-1900 (intranasal potentiated oxytocin) are ongoing for pediatric obesity, binge eating disorder, bone health in autism and social anxiety disorder TNX-2900 (intranasal [...]
CAMP4 Therapeutics Announces Dosing of First Participant in Phase 1 Clinical Study of CMP-CPS-001, a Potential First-in-Class Therapeutic for Urea Cycle Disorders
21/03/2024
Lead program in urea cycle disorders highlights power of CAMP4’s RAP Platform™ to increase gene expression using programmable, targeted medicines, with clinical candidate moving from screen-to-clinic within 3 years [...]
Context Therapeutics Reports Full Year 2023 Operating and Financial Results
21/03/2024
CTIM-76 IND filing on track for late March 2024 Cash and cash equivalents of $14.4 million as of December 31, 2023 Company expects its cash and cash equivalents will continue to fund operations into late 2024 [...]
Pyxis Oncology Provides Corporate Update and Reports Financial Results for Fourth Quarter and Full Year 2023
21/03/2024
PYX-201 Phase 1 Part 1 trial progressing with initial data expected in the fall of 2024 PYX-106 Phase 1 trial progressing with initial data expected 2H 2024 Completed $50 million private placement Expected cash runway [...]
Theratechnologies Initiates Increased Dose Level in Phase 1 Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer
21/03/2024
Medical Review Committee approved initiation of recruitment of next cohort of patients, in alignment with dose optimization protocol First patient out of six already enrolled and treated with initial dose of 2.50 mg/kg/ [...]
Theratechnologies entreprend l’augmentation de la dose dans l’essai clinique de phase I sur le sudocétaxel zendusortide dans le traitement du cancer de l’ovaire avancé
21/03/2024
Le comité d’examen médical a approuvé la mise en place du recrutement de la prochaine cohorte de patientes, conformément au protocole d’optimisation des doses Une première patiente du groupe qui en comptera six a déjà [...]
BrightSpring Health Services Recognizes its Valuable and Esteemed Female Leaders and Staff in Celebration of Women’s History Month
21/03/2024
LOUISVILLE, Ky., March 21, 2024 (GLOBE NEWSWIRE) -- This Women’s History Month, BrightSpring Health Services, Inc. (“BrightSpring” or the “BrightSpring Health Services”) (NASDAQ: BTSG) recognizes and celebrates the [...]
XOMA Declares Quarterly Preferred Stock Dividends
21/03/2024
EMERYVILLE, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced its Board of Directors has authorized the following cash dividends to holders of XOMA’s [...]
IntelGenx Reports Fourth Quarter and Full-Year 2023 Financial Results
21/03/2024
SAINT LAURENT, Quebec, March 21, 2024 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX:IGX)(OTCQB:IGXT) (the "Company" or "IntelGenx") today reported financial results for the three- and twelve-month periods ended [...]

Pages